[go: up one dir, main page]

US20030082153A1 - Stem cells that transform to beating cardiomyocytes - Google Patents

Stem cells that transform to beating cardiomyocytes Download PDF

Info

Publication number
US20030082153A1
US20030082153A1 US10/003,400 US340001A US2003082153A1 US 20030082153 A1 US20030082153 A1 US 20030082153A1 US 340001 A US340001 A US 340001A US 2003082153 A1 US2003082153 A1 US 2003082153A1
Authority
US
United States
Prior art keywords
cells
cell
growth factor
cardiomyocyte
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/003,400
Other languages
English (en)
Inventor
Neal Epstein
Thiru Gopal
Steve Winitsky
Shahin Hassanzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEALTH AND HUMAN SERVICES GOVERNMENT OF United States, Secretary of
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Priority to US10/003,400 priority Critical patent/US20030082153A1/en
Assigned to HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF, THE reassignment HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EPSTEIN, NEAL D., GOPAL, THIRU V., HASSANZADEH, SHAHIN, WINITSKY, STEVEN
Priority to CA002464088A priority patent/CA2464088A1/fr
Priority to AU2002337949A priority patent/AU2002337949B1/en
Priority to PCT/US2002/033860 priority patent/WO2003035838A2/fr
Priority to AT02773854T priority patent/ATE348878T1/de
Priority to EP02773854A priority patent/EP1444329B1/fr
Priority to DE60216959T priority patent/DE60216959D1/de
Priority to JP2003538339A priority patent/JP4377690B2/ja
Publication of US20030082153A1 publication Critical patent/US20030082153A1/en
Priority to US10/863,004 priority patent/US7220582B2/en
Priority to US11/747,060 priority patent/US20070212423A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Definitions

  • This application relates to the field of stem cells, specifically to methods of producing and differentiating muscle stem cells.
  • Heart failure may occur from a variety of causes, including cardiomyopathy, myocardial ischemia, congenital heart disease, and valvular heart disease, resulting in cardiac cell death and myocardial dysfunction.
  • cardiomyocytes are not replaced in adult myocardial tissue, physiologic demands on the existing, healthy, cardiomyocytes leads to their hypertrophy.
  • Heart transplants have been the only recourse for patients in end-stage heart disease, however the United Network of Organ Sharing (UNOS), has reported that although more than 40,000 patients were waiting for heart transplants as of February 2000, only 2,345 people received a donated heart in 1998.
  • UNOS United Network of Organ Sharing
  • heart transplants are complicated by the incompatibility between the transplanted donor tissue and the recipient's immune system, which requires life-long immunosuppression.
  • Yet another drawback of heart transplants is their high cost.
  • An alternative approach to heart transplantation is to generate cardiomyocytes from stem cells in vitro that can be used in the treatment of heart failure, and other cardiac diseases characterized by myocardial cell death or dysfunction.
  • This approach is based on the ability of stem cells to both self-renew and differentiate into one or more mature cell types, including cardiomyocytes.
  • Stem cells may be obtained from an individual suffering from heart disease and then used to generate cardiomyocytes in vitro in order to repair the damaged myocardium. This approach avoids problems inherent with heart transplantation, such as lack of a suitable heart for transplant or immune rejection of a transplanted heart.
  • Embryonic stem (ES) cells derived from the inner cell mass of the blastocyst, are the most primitive stem cell, as disclosed in WO 01/11011 A2. These cells have unlimited self-renewal capability, and because they can differentiate into several cell lineages and repopulate tissues upon transplantation, they have multipotent differentiative potential. However, protocols are not available for differentiating embryonic stem cells into beating cardiomyocytes.
  • HSC hematopoietic stem cell
  • MSC Mesenchymal stem cells
  • the methods and cells described herein are based on the ability of certain stem cells to be differentiated in vitro to form a fully functional cell of more than one given cell type.
  • spoc cells a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications.
  • FIG. 1 is a series of digital images of transmission electron micrographs demonstrating the progression of differentiation of CS (cardiac precursor from spoc cells) cells over time when cultured in differentiation medium.
  • FIG. 1A is a digital image of CS cell at day 3 with disordered myosin filaments.
  • FIG. 1B is a digital image showing that at day 7 myosin filaments of characteristic 1.6 ⁇ m-length (top box) radiate outward and the cells contain dense bodies (lower box).
  • FIG. 1C and FIG. 1F are digital images of a cell at day 14, showing a single, central nucleus shows a stretching out of the dense bodies into an organizing sarcomere.
  • FIG. 1A is a digital image of CS cell at day 3 with disordered myosin filaments.
  • FIG. 1B is a digital image showing that at day 7 myosin filaments of characteristic 1.6 ⁇ m-length (top box) radiate outward and the cells contain dense bodies (lower box).
  • FIG. 1D shows that day 3 CS cells are round cells with copious mitochondria (box and detail).
  • FIG. 1E shows elongated day 7 cells contain dense bodies (arrowhead).
  • FIG. 1G shows that by day 56, a well-defined sarcomere (FIG. 1G) is present, with identifiable A- and I-bands and Z-lines.
  • FIG. 2 demonstrates the existence of calcium transients, in cardiomyocytes differentiated from CS cells.
  • FIG. 2A shows a graphical representation of the calcium transient in a beating CS cell-derived cardiomyocyte. Peak intensity and baseline are shown in FIG. 2B and FIG. 2C, respectively.
  • DNA Deoxyribonucleic acid
  • EGF Epidermal growth factor
  • EGFP Enhanced green fluorescent protein
  • FACS Fluorescence activated cell sort
  • FBS Fetal bovine serum
  • FGF Fibroblast growth factor
  • HSC Hematopoietic stem cell
  • MRNA Messenger ribonucleic acid
  • PBS Phosphate buffered saline
  • RNase Ribonuclease
  • RT-PCR Reverse transcriptase-polymerase chain reaction
  • SPOC Skeletal-based precursors of cardiomyocytes
  • Animal Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds.
  • Cardiac Pertaining to the heart.
  • Cardiac dysfunction Any impairment in the heart's pumping function. This includes, for example, impairments in contractility, impairments in ability to relax (sometimes referred to as diastolic dysfunction), abnormal or improper functioning of the heart's valves, diseases of the heart muscle (sometimes referred to as cardiomyopathy), diseases such as angina and myocardial ischemia and infarction characterized by inadequate blood supply to the heart muscle, infiltrative diseases such as amyloidosis and hemochromatosis, global or regional hypertrophy (such as may occur in some kinds of cardiomyopathy or systemic hypertension), and abnormal communications between chambers of the heart (for example, atrial septal defect).
  • diseases of the heart muscle sometimes referred to as cardiomyopathy
  • diseases such as angina and myocardial ischemia and infarction characterized by inadequate blood supply to the heart muscle
  • infiltrative diseases such as amyloidosis and hemochromatosis
  • global or regional hypertrophy such as may occur in some kinds of cardiomyopathy or systemic hypertension
  • Cardiac muscle The heart is made of specialized muscle tissue with some similarities to both smooth and skeletal muscle. It is involuntary and mononucleate as is smooth muscle. Cardiac muscle is striated like skeletal muscle, which means that it has microscopically visible myofilaments arranged in parallel with the sarcomere. These filaments slide along each other during the process of contraction in the same manner as occurs in skeletal muscle. However, cardiac muscle contains more mitochondria so the striations are not as organized as they are in skeletal muscle. Cardiac muscle also differs from skeletal muscle in that the fibers in cardiac muscle branch and usually have a single centrally located nucleus.
  • cardiac muscle tissue Another difference in cardiac muscle is the presence of intercalated discs which serve as specialized connections between cardiac muscle cells. These tight connections allow for almost completely free movement of ions so that action potentials can freely pass from one cell to another.
  • This arrangement makes cardiac muscle tissue a functional syncytium. When one cell is excited the resultant action potential is spread to all of them.
  • Cardiac muscle can generate its own excititory impulses from the sino-atrial node, which acts like a biological pacemaker. In this manner, the contracting signal for cardiac muscles originates in the heart itself.
  • the autonomic nervous system (for example through the vagus nerve) can exert control over how fast the signals form and propagate through the heart, which regulates the rate of myocardial contraction.
  • a “cardiomyocyte” is a cell of the cardiac muscle.
  • Cardiac precursors from spoc cells (CS cells): When spoc cells are isolated from skeletal muscle and are cultured under growth conditions designed to promote their growth, spoc cells undergo several rounds of division. During this proliferative phase they become clusters of floating round cells with an increased diameter as compared to spoc cells. These round cells, with an increased diameter, are referred to as CS cells. In one embodiment, a diameter of a CS cell is from about 10 to about 14 ⁇ m. When placed in growth promoting conditions in vitro (such as the examples described below) CS cells differentiate into spontaneously beating cardiomyocytes.
  • Cardiomyopathy Any disease or dysfunction of the myocardium (heart muscle) in which the heart is abnormally enlarged, thickened and/or stiffened. As a result, the heart muscle's ability to pump blood is usually weakened.
  • the disease or disorder can be, for example, inflammatory, metabolic, toxic, infiltrative, fibroplastic, hematological, genetic, or unknown in origin.
  • cardiomyopathies There are two general types of cardiomyopathies: ischemic (resulting from a lack of oxygen) and nonischemic.
  • Ischemic cardiomyopathy is a chronic disorder caused by coronary artery disease—a disease in which there is atherosclerotic narrowing or occlusion of the coronary arteries on the surface of the heart. Coronary artery disease often leads to episodes of cardiac ischemia, in which the heart muscle is not supplied with enough oxygen-rich blood. Eventually, the heart muscle enlarges from the additional work it must do in the absence of sufficient oxygen-rich blood.
  • Nonischemic cardiomyopathy is generally classified into three groups based primarily on clinical and pathological characteristics:
  • dilated cardiomyopathy a syndrome characterized by cardiac enlargement and impaired systolic function of one or both ventricles
  • hypertrophic cardiomyopathy herein defined as (a) global or regional increase in thickness of either ventricular wall or the interventricular septum, or (b) an increased susceptibility to global or regional increase in thickness of either ventricular wall or the interventricular septum, such as can occur in genetic diseases, hypertension, or heart valve dysfunction; or
  • restrictive and infiltrative cardiomyopathies a group of diseases in which the predominant clinical feature is usually impaired ability of the heart to relax (diastolic dysfunction), and is often characterized by infiltration of the heart muscle with foreign substances such as amyloid fibers, iron, or glycolipids.
  • Cell surface marker A protein, glycoprotein, or other molecule expressed on the surface of a cell, which serves to help identify the cell.
  • a cell surface marker can generally be detected by conventional methods. Specific, non-limiting examples of methods for detection of a cell surface marker are immunohistochemistry, fluorescence activated cell sorting (FACS), or an enzymatic analysis.
  • FACS fluorescence activated cell sorting
  • Congenital heart disease A heart-related problem that is present since birth and often as the heart is forming even before birth. Congenital heart disease may affect the heart, the heart's valves, the veins leading to, or the arteries leading away, from the heart, or the connections between these parts of the body.
  • Differentiation The process whereby relatively unspecialized cells (e.g., stem cells) acquire specialized structural and/or functional features characteristic of mature cells. Similarly, “differentiate” refers to this process. Typically, during differentiation, cellular structure alters and tissue-specific proteins appear.
  • the term “differentiated muscle cell” refers to cells expressing a protein characteristic of the specific muscle cell type.
  • a differentiated muscle cell includes a skeletal muscle cell, a smooth muscle cell, and a cardiac muscle cell.
  • Differentiation Medium A synthetic set of culture conditions with the nutrients necessary to support the growth or survival of cultured cells, and which allows the differentiation of stem cells into differentiated cells.
  • DNA Deoxyribonucleic acid.
  • DNA is a long chain polymer which comprises the genetic material of most living organisms (some viruses have genes comprising ribonucleic acid (RNA)).
  • the repeating units in DNA polymers are four different nucleotides, each of which comprises one of the four bases, adenine, guanine, cytosine and thymine bound to a deoxyribose sugar to which a phosphate group is attached.
  • Triplets of nucleotides (referred to as codons) code for each amino acid in a polypeptide.
  • codon is also used for the corresponding (and complementary) sequences of three nucleotides in the mRNA into which the DNA sequence is transcribed.
  • EGF Epidermal growth factor
  • EGF is a globular protein of 6.4 kDa consisting of 53 amino acids. It contains three intramolecular disulfide bonds essential for biological activity. EGF proteins are evolutionarily closely conserved. Human EGF and murine EGF have 37 amino acids in common. Approximately 70 percent homology is found between human EGF and EGF isolated from other species. Mammalian EGF includes, but is not limited to, murine, avian, canine, bovine, porcine, equine, and human EGF. The amino acid sequences and methods for making these EGF polypeptides are well known in the art.
  • the gene encoding the EGF precursor has a length of approximately 110 kb, and contains 24 exons. Fifteen of these exons encode protein domains that are homologous to domains found in other proteins.
  • the human EGF gene maps to chromosome 4q25-q27.
  • EGF is a strong mitogen for many cells of ectodermal, mesodermal, and endodermal origin. EGF controls and stimulates the proliferation of epidermal and epithelial cells, including fibroblasts, kidney epithelial cells, human glial cells, ovary granulosa cells, and thyroid cells in vitro. EGF also stimulates the proliferation of embryonic cells. However, the proliferation of some cell lines has been shown to be inhibited by EGF.
  • EGF is also known to act as a differentiation factor for some cell types. It strongly influences the synthesis and turn-over of proteins of the extra-cellular matrix including fibronectin, collagen, laminin, and glycosaminoglycans, and has been shown to be a strong chemoattractant for fibroblasts and epithelial cells.
  • EGF can be assayed in a cell-based assay wherein the proliferation of a cell population is assessed. EGF can also be assayed by an immunoassay, such as an ELISA assay.
  • EGF variants smaller than the full-length sequence can also be employed in methods disclosed herein. Suitable biologically active variants can also be utilized.
  • EGF variant of use is an EGF sequence having one or more amino acid substitutions, insertions, or deletions, wherein a biological function of EGF is retained.
  • Another specific, non-limiting example of an EGF variant is EGF as wherein glycosylation or phosphorylation is altered, or a foreign moiety is added, so long as a biological function of EGF is retained.
  • Methods for making EGF fragments, analogues, and derivatives are available in the art. Examples of EGF variants are known in the art, for example U.S. Pat. No. 5,218,093 and WO 92/16626A1. Examples of EGF from many different species are disclosed in WO 92/16626A1, as are examples of variants, and strategies for producing them.
  • EGF refers to naturally occurring EGF, and variants and fragments that perform the same function of EGF in the culture media disclosed herein.
  • Embryonic stem (ES) cells are totipotent cells isolated from the inner cell mass of the developing blastocyst and can generate all of the cells present in the body (bone, muscle, brain cells, etc.). “ES cells” can be derived from any organism, for example from mammals such as humans.
  • Fibroblast growth factor Any suitable fibroblast growth factor, derived from any animal, and functional variants and fragments thereof.
  • FGFs include, but are not limited to, FGF-1 (acidic fibroblast growth factor), FGF-2 (basic fibroblast growth factor, bFGF), FGF-3 (int-2), FGF-4 (hst/K-FGF), FGF-5, FGF-6, FGF-7, FGF-8, and FGF-9.
  • FGF refers to a fibroblast growth factor protein such as FGF-1, FGF-2, FGF-4, FGF-6, FGF-8, or FGF-9, or a biologically active fragment or mutant thereof.
  • the FGF can be from any animal species.
  • the FGF is mammalian FGF including but not limited to, rodent, avian, canine, bovine, porcine, equine, and human.
  • the amino acid sequences and method for making many of the FGFs are well known in the art.
  • Suitable biologically active variants can be FGF analogues or derivatives.
  • An analogue of FGF is either FGF or an FGF fragment that includes a native FGF sequence and structure having one or more amino acid substitutions, insertions, or deletions. Analogs having one or more peptoid sequences (peptide mimic sequences) are also included (see e.g. International Publication No. WO 91/04282).
  • derivative is intended any suitable modification of FGF, FGF fragments, or their respective analogues, such as glycosylation, phosphorylation, or other addition of foreign moieties, so long as the FGF activity is retained. Methods for making FGF fragments, analogues, and derivatives are available in the art.
  • Growth factor A substance that promotes cell growth, survival, and/or differentiation. In general, growth factors stimulate cell proliferation or maturation when they bind to their receptor. In one embodiment, growth factors are a complex family of polypeptide hormones or biological factors that control growth, division, and maturation of muscle cells. In another embodiment a growth factor can be used to promote the proliferation of muscle stem cells and maintain the stem cells in an undifferentiated state.
  • a growth factor can be a naturally occurring factor or a factor synthesized using molecular biology techniques.
  • growth factors examples include platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, insulin, somatomedin, stem cell factor, vascular endothelial growth factor, granulocyte colony stimulating factor, and transforming growth factor-beta, amongst others.
  • a muscle cell growth factor is a growth factor that effects the development (maturation), differentiation, division, or proliferation of muscle cells.
  • Growth medium A synthetic set of culture conditions with the nutrients necessary to support the growth or survival of microorganisms or culture cells.
  • Heart The muscular organ of an animal that circulates blood.
  • the walls of the heart are comprised of working muscle, or myocardium, and connective tissue.
  • Myocardium is comprised of myocardial cells, which are also referred to herein as cardiac cells, cardiac myocytes, cardiomyocytes and/or cardiac fibers.
  • Cardiomyocytes may be cells of the atrium or cells of the ventricle.
  • Heart failure The inability of the heart to supply sufficient oxygenated blood to meet the metabolic needs of the tissues and cells in a subject. This can be accompanied by circulatory congestion, such as congestion in the pulmonary or systemic veins.
  • heart failure encompasses heart failure from any cause, and is intended herein to encompass terms such as “congestive heart failure,” “forward heart failure,” “backward heart failure,” “high output heart failure,” “low output heart failure,” and the like. See Chapters 13-17 in Braunwald for a detailed discussion. Conditions that could lead to heart failure include, but are not limited to, coronary artery disease, cardiomyopathy, or congenital heart disease.
  • heterologous sequence is a sequence that is not normally (i.e. in the wild-type sequence) found adjacent to a second sequence.
  • the sequence is from a different genetic source, such as a virus or organism, than the second sequence.
  • Isolated An “isolated” biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles.
  • Nucleic acids and proteins that have been “isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.
  • Mammal This term includes both human and non-human mammals. Similarly, the term “subject” includes both human and veterinary subjects.
  • Muscle cell Includes skeletal, cardiac or smooth muscle tissue cells. This term is synonymous with myocyte, and encompasses those cells which differentiate to form more specialized muscle cells (e.g. myoblasts). “Cardiomyocyte” refers to a cardiac muscle cell.
  • Myocardial injury Damage to the muscle or the “myocardium” in the wall of the heart as a result of disease or trauma.
  • Myocardial injury can be attributed to many things such as, but not limited to, cardiomyopathy, myocardial infarction, or congenital heart disease.
  • Nucleotide includes, but is not limited to, a monomer that includes a base linked to a sugar, such as a pyrimidine, purine or synthetic analogs thereof, or a base linked to an amino acid, as in a peptide nucleic acid (PNA).
  • a nucleotide is one monomer in a polynucleotide.
  • a nucleotide sequence refers to the sequence of bases in a polynucleotide.
  • Operably linked A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.
  • compositions and formulations suitable for pharmaceutical delivery of stem cells herein disclosed are known.
  • Remington's Pharmaceutical Sciences by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of stem cells herein disclosed.
  • parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • Pharmaceutical agent refers to a chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject or a cell. “Incubating” includes exposing a target to an agent for a sufficient period of time for the agent to interact with a cell. “Contacting” includes incubating an agent in solid or in liquid form with a cell.
  • Polypeptide refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds.
  • the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being preferred.
  • polypeptide or “protein” as used herein is intended to encompass any amino acid sequence and include modified sequences such as glycoproteins.
  • polypeptide is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced.
  • polypeptide fragment refers to a portion of a polypeptide which exhibits at least one useful epitope.
  • functional fragments of a polypeptide refers to all fragments of a polypeptide that retain an activity of the polypeptide.
  • Biologically functional fragments can vary in size from a polypeptide fragment as small as an epitope capable of binding an antibody molecule to a large polypeptide capable of participating in the characteristic induction or programming of phenotypic changes within a cell.
  • An “epitope” is a region of a polypeptide capable of binding an immunoglobulin generated in response to contact with an antigen. Thus, smaller peptides containing the biological activity of insulin, or conservative variants of the insulin, are thus included as being of use.
  • soluble refers to a form of a polypeptide that is not inserted into a cell membrane.
  • substantially purified polypeptide refers to a polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
  • the polypeptide is at least 50%, for example at least 80% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
  • the polypeptide is at least 90% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
  • the polypeptide is at least 95% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
  • Variations in the cDNA sequence that result in amino acid changes, whether conservative or not, are usually minimized in order to preserve the functional and immunologic identity of the encoded protein.
  • the immunologic identity of the protein may be assessed by determining whether it is recognized by an antibody; a variant that is recognized by such an antibody is immunologically conserved. Any cDNA sequence variant will preferably introduce no more than twenty, and preferably fewer than ten amino acid substitutions into the encoded polypeptide.
  • Variant amino acid sequences may, for example, be 80, 90 or even 95% or 98% identical to the native amino acid sequence. Programs and algorithms for determining percentage identity can be found at the NCBI website.
  • Precursor Cell A cell that can generate a fully differentiated functional cell of at least one given cell type. Generally, precursor cells can divide. After division, a precursor cell can remain a precursor cell, or may proceed to terminal differentiation.
  • a “muscle precursor cell” is a precursor cell that can generate a fully differentiated functional muscle cell, such as a cardiomyocyte or a skeletal muscle cell.
  • a muscle precursor cell is a “cardiac precursor cell,” which is a cell that gives rise to cardiac muscle cells.
  • Progenitor Cell A cell that gives rise to progeny in a defined cell lineage.
  • a “muscle progenitor cell” is a cell that gives rise to cells of the muscle lineage.
  • One specific, non-limiting, example of a skeletal muscle progenitor cell is a “satellite cell,” which gives rise to immature and mature skeletal muscle cells.
  • a recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.
  • a recombinant protein is one encoded for by a recombinant nucleic acid molecule.
  • Skeletal muscle makes up most of the body's muscle and does not contract without nervous stimulation. It is under voluntary control and lacks anatomic cellular connections between fibers.
  • the fibers (cells) are multinucleate and appear striated due to the arrangement of actin and myosin protein filaments. Each fiber is a single cell, long, cylindric and surrounded by a cell membrane.
  • the muscle fibers contain many myofibrils that are made of myofilaments. These myofilaments are made up of contractile proteins.
  • the key proteins in muscle contraction are myosin, actin, tropomyosin and troponin.
  • Skeletal-based precursor of cardiomyocytes Stem cells derived from skeletal muscle, which do not express the cell surface markers c-met, or c-kit, that can be differentiated into cardiomyocytes.
  • spoc cells are muscle derived precursor cells that are about 4 ⁇ m in diameter when cultured in vitro. These cells remain in suspension and proliferate when cultured in the presence of a growth factor.
  • growth factors of use in propagating spoc cell are FGF, EGF, or a combination thereof.
  • spoc cells differentiate into spontaneously beating cardiomyocytes in vitro.
  • a proliferative phase e.g. about 7 days after being maintained in vitro in the presence of a growth factor
  • spoc cells cluster and increase in size to about 10-14 ⁇ m in diameter.
  • the cells in these clusters referred to as CS cells, have the ability to differentiate into mature cardiac muscle cells when cultured in the absence of growth factors.
  • Spontaneous arising from an internal cause, resulting from internal or natural processes, with no apparent external influence.
  • a “spontaneously beating cardiomyocyte” is a cell that begins to beat as a result of internal signals.
  • Stem cell refers to a cell that can generate a fully differentiated functional cell of more than one given cell type.
  • the role of stem cells in vivo is to replace cells that are destroyed during the normal life of an animal.
  • stem cells can divide without limit. After division, the stem cell may remain as a stem cell, become a precursor cell, or proceed to terminal differentiation. Although appearing morphologically unspecialized, the stem cell may be considered differentiated where the possibilities for further differentiation are limited.
  • a “muscle stem cell” is a stem cell derived from muscle or that gives rise to muscle cells after differentiation.
  • a muscle stem cell is a cell that gives rise to cardiac muscle cells.
  • Subject refers to any mammal, such as humans, non-human primates, pigs, sheep, cows, rodents and the like which is to be the recipient of the particular treatment.
  • a subject is a human subject or a murine subject.
  • Suspension a dispersion of solid particles, such as a cell, throughout the body of a liquid, such as a culture medium or an isotonic (physiologically compatible) buffer.
  • Therapeutic agent Used in a generic sense, it includes treating agents, prophylactic agents, and replacement agents.
  • Therapeutically effective amount is the amount of agent that is sufficient to prevent, treat, reduce and/or ameliorate the symptoms and/or underlying causes of any of a disorder or disease.
  • a “therapeutically effective amount” is sufficient to reduce or eliminate a symptom of a cardiac disease.
  • a therapeutically effective amount is an amount sufficient to overcome the disease itself.
  • a therapeutically effective amount of a cell can be administered in a single dose, or in several doses, for example daily, during a course of treatment. However, the effective amount of the cells will be dependent on the subject being treated, the severity and type of the condition, and the manner of administration of the compound. “Administering” can be accomplished by introducing the therapeutically effective amount locally or systemically into the subject. Systemic introduction can be accomplished by using an intravenous, intramuscular, transcutaneous or subcutaneous means. Such means could include introducing the therapeutically effective amount via injection, or via catheter.
  • administering a therapeutically effective amount to the subject is understood to include all animals (e.g. humans, apes, dogs, cats, horses, and cows) that have or may develop some form of cardiac dysfunction.
  • transfected cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques.
  • transduction encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transduction with viral vectors, transformation with plasmid vectors, and introduction of DNA by electroporation, lipofection, and particle gun acceleration.
  • Transplantation The transfer of a tissue or an organ, or a portion thereof, from one body or part of the body to another body or part of the body.
  • Vector A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell.
  • Recombinant DNA vectors are vectors having recombinant DNA.
  • a vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
  • a vector can also include one or more selectable marker genes and other genetic elements known in the art.
  • Viral vectors are recombinant DNA vectors having at least some nucleic acid sequences derived from one or more viruses.
  • spoc cells Stem cells derived from skeletal muscle (spoc cells) are disclosed herein.
  • Spoc cells do not express the cell surface markers c-met, or c-kit, and are thus termed a c-met ⁇ /c-kit ⁇ cell.
  • Spoc cells can be isolated from any age mammal, either human or non-human.
  • spoc cells can be obtained from a fetus, a child or an adult of any mammalian species.
  • a spoc cell is human or murine c-met ⁇ /c-kit ⁇ cell that can be differentiated into a cardiomyocyte in vitro.
  • the spoc cell is between about 3 ⁇ m and 10 ⁇ m in diameter, or are about 4 ⁇ m in diameter.
  • spoc cells do not adhere to the culture dish but remain in suspension when cultured in the presence of at least one growth factor.
  • the growth factor is EGF.
  • the growth factor is FGF.
  • spoc cells are also disclosed herein (see below) for differentiating spoc cells.
  • the differentiation of spoc cells into cardiomyocytes can be assessed by observing morphological changes.
  • differentiated spoc cells are spontaneously beating cardiomyocytes.
  • organized gap junctions and sarcomeres with clear Z-lines and A- and I-bands are observed in the differentiated spoc cells.
  • certain examples of the differentiated spoc cells may be mono- or multi-nucleate. In one embodiment the cells are bi-nucleate.
  • the isolated spoc cell can be transduced using standard procedures known in molecular biology in order to introduce a nucleic acid molecule of interest into the cell.
  • the nucleic acid molecule encodes a polypeptide.
  • the polypeptide encoded by the nucleic acid molecule can be from the same species as the cells (homologous), or can be from a different species (heterologous).
  • a nucleic acid molecule can be utilized that supplements or replaces deficient production of a peptide by the tissue of the host wherein such deficiency is a cause of the symptoms of a particular disorder.
  • the cells act as a source of the peptide.
  • the polypeptide is the cardiac specific transcription factor GATA-4.
  • the nucleic acid molecule of interest encodes a polypeptide involved in growth regulation or neoplastic transformation of cardiac cells.
  • nucleic acids sequences of interest are SV40 Tag, p53, myc, src, and bcl-2.
  • the nucleic acid sequence of interest encodes an enzyme.
  • enzymes are proteins involved in the conversion of a pro-drug to a drug, or growth factors that promote the expansion, differentiation, or survival of cardiac progenitor cells, such as EGF, FGF, or atrial natriuretic factor.
  • the nucleic acid sequence of interest encodes a transcriptional regulator.
  • the nucleic acid sequence of interest is operably linked to a regulatory element, such as a transcriptional and/or translational regulatory element.
  • Regulatory elements include elements such as a promoter, an initiation codon, a stop codon, mRNA stability regulatory elements, and a polyadenylation signal.
  • a promoter can be a constitutive promoter or an inducible promoter. Specific non-limiting examples of promoters include the CMV promoter, an atrial natriuretic factor promoter, and promoters including TET-responsive element for inducible expression of transgene.
  • the nucleic acid sequence of interest is inserted into a vector, such as an expression vector.
  • a nucleic acid sequence can be introduced to decrease rejection.
  • the immunogenicity of a cell may be suppressed by deleting genes that produce proteins that are recognized as “foreign” by the host (a knock-out), or by introducing genes which produce proteins, such as proteins that are native to the host and recognized as “self” proteins by the host immune system.
  • a spoc cell may be transfected with a nucleic acid molecule designed to functionally delete or “knock-out” a gene of interest.
  • the nucleic acid molecule of interest is a nucleic acid molecule that undergoes homologous recombination and is inserted into the genome of the spoc cell.
  • Methods for producing “knock-outs” in ES cells are known to one of skill in the art (e.g. see U.S. Pat. No. 5,939,598).
  • cells are cultured in vitro as described herein and an exogenous nucleic acid is introduced into the cells by any method known to one of skill in the art, for example, by transfection or electroporation.
  • the transfected cultured cells can then be studied in vitro or can be administered to a subject (see below).
  • Methods for the introduction of nucleic acid sequences into stem cells are known in the art (e.g., see U.S. Pat. No. 6,110,743).
  • spoc cell A method of isolating a c-met ⁇ /c-kit ⁇ cardiomyocyte precursor cell of muscular origin (spoc cell) is described herein.
  • spoc cells are separated by size from a suspension of muscle cells and the cells are cultured on a solid substrate. The cells that remain in suspension in the culture medium are isolated.
  • the method of isolation of the spoc cells includes obtaining the cells from the muscle of a subject.
  • Muscle tissue can be prepared for the purpose of isolating or obtaining individual spoc cells by using methods well known to one of skill in the art. Examples of methods of tissue preparation include enzymatic digestion with enzymes such as collagenase, mechanical disruption using instruments such as hand-held or motor-driven homogenizers, or by chemical disruption using, for example, chelators of calcium and magnesium.
  • the preparation of muscle cells can be sorted by any method that separates cells on the basis of cell size.
  • the spoc cells are isolated by passing digested skeletal muscle through a series of filters of varying pore size. The cells are passed through two filters, where a first filter has a pore size of about 50-200 ⁇ m, about 60-150 ⁇ m, about 80-100 ⁇ m, or about 100 ⁇ m and a second filter has a pore size of about 10-50 ⁇ m, 20-40 ⁇ m, or about 40 ⁇ m.
  • the isolated cells are less than 40 ⁇ m in diameter.
  • isolated cells are between about 3 ⁇ m and 10 ⁇ m in diameter. In another embodiment the isolated cells are about 4 ⁇ m in diameter.
  • the cells can be also sorted by size by passing them through size-exclusion columns.
  • the cells are eluted along a size gradient such that the largest cells are eluted first and the smallest cells are eluted last.
  • the cells can also be sorted by size using FACS. Cells of about 3 ⁇ m to 10 ⁇ m in diameter, or of about 4 ⁇ m in diameter, are isolated.
  • the cells are further selected and then expanded in culture medium.
  • the cells are cultured on a solid substrate that permits the adhesion of a subpopulation of cells in the presence of a culture medium.
  • the solid substrate is a container, such as a tissue culture dish.
  • the solid substrate is in the form of beads designed for tissue culture.
  • the medium can be a growth medium, or any buffer that maintains the viability of the cells.
  • a variety of culture media are known and are suitable for use.
  • the growth medium includes a minimal essential medium.
  • the medium is DMEM and/or F12, or a combination of DMEM and F12 (at a ratio between about 1:1 to about 10:1).
  • the growth medium may be supplemented with serum.
  • serum are horse, calf or fetal bovine serum.
  • the medium can have between about 3% by volume to about 10% by volume serum, or about 5% by volume serum.
  • the medium contains one or more additional additives such as nutrients.
  • additional additives such as nutrients.
  • Additive Exemplary Concentration serum About 3% to about 10% insulin About 5 ⁇ g/ml to about 10 ⁇ g/ml transferrin About 5 ⁇ g/ml to about 10 ⁇ g/ml selenium About 6 ng/ml ethanolamine About 2 ⁇ g/ml EGF About 5 ng/ml to about 10 ng/ml FGF About 5 ng/ml to about 10 ng/ml gentamycin About 25 ⁇ g/ml to about 50 ⁇ g/ml fungizone About 0.2 ⁇ g/ml to about 2.5 ⁇ g/ml
  • the muscle stem cell growth media can also be supplemented with growth factors.
  • the growth medium includes basic fibroblast growth factor (bFGF).
  • bFGF basic fibroblast growth factor
  • the growth medium includes between about 2 ng/ml to about 100 ng/ml of bFGF, such as for example between about 5 ng/ml to about 50 ng/ml, between about 8 ng/ml to about 20 ng/ml, or between about 5 to about 10 ng/ml bFGF.
  • the medium includes about 10 ng/ml bFGF.
  • the growth medium includes epidermal growth factor (EGF).
  • the growth medium includes between about 2 ng/ml to about 100 ng/ml of EGF, such as for example between about 5 ng/ml to about 50 ng/ml, between about 8 ng/ml to about 20 ng/ml, or between about 5 ng/ml to about 10 ng/ml EGF.
  • the medium includes about 10 ng/ml EGF.
  • the growth medium is 1:1 DMEM/F 12 and includes 5% fetal bovine serum, 10 ng/ml FGF, 10 ng/ml EGF, 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 6 ng/ml selenium, 2 ⁇ g/ml ethanolamine.
  • the cells are cultured in the growth medium for about 4 days to about 8 days. In another specific, non-limiting example, the cells are cultured in the growth medium for about 6 days to about 7 days.
  • the cells cluster and increase in size. Within the clusters the cells are between about 5-20 ⁇ m in diameter, or between about 10-14 ⁇ m in diameter.
  • a method for isolating spoc cells wherein the spoc cells are identified using specific binding agents, such as antibodies, for example monoclonal antibodies that recognize cell surface markers.
  • This particular method of isolation of the spoc cells includes obtaining the cells from the muscle of a subject, as described above.
  • the cells are selected by size (see above) and then the c-met ⁇ /c-kit ⁇ spoc cells are identified using the specific binding agents, such as antibodies that recognize the c-met and c-kit cell surface markers.
  • the c-met and c-kit antibodies are immobilized.
  • a particular embodiment uses magnetic cell sorting. This method involves a combination of monoclonal antibodies which are covalently bound to the surface of magnetic beads and which are directed to cell surface markers which are absent from the cells being selected. For example, to isolate the c-met ⁇ /c-kit ⁇ spoc cells, monoclonal antibodies to c-met and c-kit bound to magnetic beads are used. All cells expressing either c-met, or c-kit, or both c-met and c-kit, will be bound by the antibodies and retained by the beads. Since the cells bound to the magnetic beads are immobilized by the magnet, the c-met ⁇ /c-kit ⁇ cells that remain in suspension can be isolated from the other cells.
  • purified populations of c-met ⁇ /c-kit ⁇ spoc cells are isolated via FACS. Fluorescent-tagged antibodies against c-met and c-kit identify c-met+, c-kit+ and c-met+/c-kit+ double-positive populations of cells, allowing for the identification and isolation of the double-negative c-met ⁇ /c-kit ⁇ population.
  • a single antibody, or a combination of antibodies can be covalently bound to inert beads, such as sepharose beads.
  • the beads can be packed in a column or maintained as a slurry.
  • the cells expressing one or more of the cell surface markers are recognized by one or more of the antibodies, thus becoming bound to the beads, thereby identifying a subpopulation of unbound cells that does not express the combination of cell surface markers.
  • the antibodies are not immobilized.
  • the addition of the antibodies to a mixture of cells causes the aggregation of cells expressing the cell surface markers recognized by the antibodies.
  • the cells not expressing the cell surface markers are excluded from the aggregates and can be isolated.
  • Spoc cells isolated by these or other methods can be maintained in culture.
  • the spoc cells can further be differentiated into cardiomyocytes.
  • a method for differentiating a spoc cell into a cardiomyocyte.
  • the cardiomyocyte is a spontaneously beating cardiomyocyte.
  • differentiation into cardiomyocytes is induced by culturing cells in medium similar to the growth medium, but which does not include at least one growth factor.
  • a specific, non-limiting example of a differentiation medium is a growth medium that lacks at least one growth factor. Growth factors removed from the medium include, but are not limited to, bFGF or EGF, or a combination of bFGF and EGF.
  • Removal of at least one growth factor causes the cells to adhere to the tissue culture dish and acquire characteristics of a differentiated cardiomyocyte.
  • Differentiation refers to the process whereby relatively unspecialized cells, such as the c-met ⁇ /c-kit ⁇ muscle-derived stem cells acquire specialized structural and/or functional features characteristic of mature cells, such as cardiomyocytes.
  • c-met ⁇ /c-kit ⁇ muscle stem cells into cardiomyocytes can be measured by any method known to one of skill in the art.
  • Specific, non-limiting examples are immunohistochemical analysis to detect expression of cardiac polypeptides (e.g. troponin-T, L-type calcium channel, or cardiac-specific transcription factors GATA-4, or Nkx2.5), or assays such as ELISA assay and Western blot analysis.
  • Differentiation of cells can also be measured by assaying the level of mRNA coding for cardiac polypeptides using techniques such as Northern blot, RNase protection and RT-PCR. In another embodiment, the number of spontaneously beating cells is assessed.
  • Calcium transients can be used as a measure of cardiomyocyte differentiation.
  • calcium imaging is used to measure calcium transients.
  • ratiometric dyes such as fura-2, fluo-3, or fluo-4 are used to measure intracelluar calcium concentration.
  • the relative calcium levels in a population of cells treated with a ratiometric dye can be visualized using a fluorescent microscope or a confocal microscope.
  • the membrane potential across the cell membrane is monitored to assess calcium transients. For example, a voltage clamp is used. In this method, an intracellular microelectrode is inserted into the cardiomyocyte.
  • calcium transients can be seen before observable contractions of the cardiomyocytes. In other embodiments calcium transients are seen either during, or after, observable contractions of cardiomyocytes. In another embodiment the cells are cultured in the presence of conditions wherein the cells do not beat, such as in the presence of a calcium chelator (e.g. EDTA or EGTA) and the calcium transients are measured.
  • a calcium chelator e.g. EDTA or EGTA
  • methods are provided for treating a subject suffering from a disease or a disorder, such as myocardial injury, or alleviating the symptoms of such a disorder, by administering cells isolated and cultured according to the methods disclosed.
  • spoc cells are isolated as described herein and a therapeutically effective amount of spoc cells is administered to the subject.
  • spoc cells are isolated and differentiated into cardiomyocytes, as disclosed above, and a therapeutically effective amount of the differentiated cells are administered to a subject, such as a human.
  • the cells may be administered in any fashion, for example in a dose of, for example 0.25-1.0 ⁇ 10 6 cells. Different dosages can of course be used depending on the clinical circumstances.
  • the cells may be administered systemically (for example intravenously) or locally (for example directly into a myocardial defect under echocardiogram guidance, or by direct application under visualization during surgery).
  • the cells are administered in a gel matrix (such as Gelfoam from Upjohn Company) which polymerizes to form a substrate in which the administered cells can grow.
  • the subject has a myocardial injury.
  • the myocardial injury may be due to trauma that occurred as the result of an object or projectile, such as a knife or a bullet, having penetrated the myocardium, or as a consequence of surgery to remove, for example, a tumor.
  • Myocardial injury may also result from diseases such as cardiomyopathy, myocardial infarction, or congenital heart disease.
  • the subject is suffering from cardiac dysfunction which includes, for example, abnormal or improper functioning of the heart valves, or abnormal communication between the chambers of the heart.
  • the spoc cells or differentiated cardiomyocytes are administered systemically by injection.
  • Specific, non-limiting examples include administration by subcutaneous injection, intramuscular injection, or intravenous injection. If administration is intravenous, an injectible liquid suspension of spoc cells can be prepared and administered by a continuous drip or as a bolus.
  • the spoc cells or differentiated cardiomyocytes are administered locally.
  • local administration is intra-cardiac muscle injection.
  • the spoc cells are in an injectible liquid suspension preparation or in a biocompatible medium which is injectible in liquid form and becomes semi-solid at the site of damaged myocardium.
  • a conventional intra-cardiac syringe or a controllable endoscopic delivery device can be used so long as the needle lumen or bore is of sufficient diameter (e.g. 30 gauge or larger) that shear forces will not damage the spoc cells.
  • the cells are administered locally on a support medium.
  • a support medium is a sterile mesh, or matrix, upon which the cardiomyocytes are cultured.
  • a layer of cardiomyocytes, for example a confluent layer of cardiomyocytes, cultured on such a matrix can be applied locally, or grafted at or near, a site of myocardial injury.
  • the support medium is a biodegradable mesh. In another embodiment the support medium is not biodegradable. The size of the mesh, and the density of cells on it, can vary depending on the myocardial defect being treated.
  • the cells are encapsulated prior to administration, such as by co-incubation with a biocompatible matrix known in the art.
  • a biocompatible matrix known in the art.
  • encapsulation technologies have been developed (e.g. Lacy et al., Science 254:1782-84, 1991; Sullivan et al., Science 252:7180712, 1991; WO 91/10470; WO 91/10425; U.S. Pat. No. 5,837,234; U.S. Pat. No. 5,011,472; U.S. Pat. No. 4,892,538).
  • the cells can be repeatedly administered at intervals until a desired therapeutic effect is achieved.
  • methods are provided for screening agents that affect cardiomyocyte differentiation or function.
  • a population of cardiomyocytes or their precursors is produced as described above.
  • the population of cells is contacted with an agent of interest, and the effect of the agent on the cell population is then assayed.
  • the effect on differentiation, survival, proliferation, or function of the cells is assessed.
  • the methods described herein can be used to assess the effect of an agent on cardiomyocyte differentiation.
  • the agent is contacted either to spoc cells or CS cells.
  • the spoc cells are maintained in medium including a growth factor between about 1 day to about 8 days, between about 4 days to about 7 days, or about 7 days before the addition of an agent.
  • the growth factor is removed from the medium, generating CS cells, at or before the agent is added.
  • CS cells are maintained in the medium between about 1 day to about 56 days, between about 7 days to about 28 days, or between about 14 days to about 21 days before the addition of an agent.
  • Differentiation of spoc cells contacted with an agent can be assessed by any means known to one of skill in the art.
  • the morphology is examined, for example electron microscopy is used to assess the ultrastructure of the cells.
  • Suitable parameters for evaluation include, but are not limited to the evaluation of gap junctions between contacting cardiomyocytes.
  • immunohistochemical or immunofluorescence techniques are used to assess differentiation.
  • differentiation is assessed by analysis expression of specific mRNA molecules expressed in cardiomyocytes. Suitable assay systems include, but are not limited to RT-PCR, in situ hybridization, Northern analysis, or RNase protection assays.
  • the levels of polypeptides expressed in differentiated cardiomyocytes are assayed. Specific, non-limiting examples of polypeptide assays of use include Western blot analysis, ELISA assay, or immunofluorescence. Alternatively, calcium transients are measured, as described above.
  • the assay can also be used to screen the effect of an agent on cardiomyocyte function. Any method known to one of skill in the art can be utilized to assess cardiac function.
  • the beating rate of a cardiomyocyte is assayed to identify agents that increase or decrease beating.
  • One method for assessing the beating rate is to observe beating under a microscope.
  • Agents that can be screened in this manner include inotropic drugs, such as sympathomimetic agents.
  • cells contacted with the agent are compared with a control.
  • Suitable controls include spoc or CS cells not contacted with the agent, or contacted with vehicle alone. Standard values can also be used as a control.
  • the cells described herein are ideally suited for the preparation of a kit.
  • the kit can include a carrier means, such as a box, a bag, or plastic carton.
  • the carrier contains one or more containers such as vials, tubes, and the like that include a sample of spoc cells.
  • the carrier includes a container with an agent that affects differentiation, a buffer, or a vehicle for the introduction of the cells.
  • Instructions can be provided to detail the use of the components of the kit, such as written instructions, video presentations, or instructions in a format that can be opened on a computer (e.g. a diskette or CD-ROM disk). These instructions indicate, for example, how to administer the cells to treat a myocardial defect or how to use the cells to screen test agents of interest (such as inotropic drugs).
  • the spoc cells were plated at a density of approximately 10 5 cells per cm 2 in regular tissue culture dishes in complete growth medium (1:1 DMEM/F12 supplemented with 5% fetal bovine serum (FBS), 10 ng/ml human EGF, 10 ng/ml human bFGF (PeproTech, Inc.), 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 6 ng/ml selenium, 2 ⁇ g/ml ethanolamine (ITS-X, Invitrogen Corporation), 25 ⁇ g/ml gentamicin and 2.5 ⁇ g/ml fungizone (Life Technologies)).
  • FBS fetal bovine serum
  • 10 ng/ml human EGF 10 ng/ml human bFGF
  • 5 ⁇ g/ml insulin 5 ⁇ g/ml transferrin
  • 6 ng/ml selenium 2 ⁇ g/ml ethanolamine (ITS-X, Invitrogen Corporation)
  • ITS-X
  • the culture consisted of a floating population of round cells and some adherent fibroblasts.
  • the round cells enlarged as they underwent a few rounds of cell division during which time they became clusters of floating round cells with an increased diameter of 10-14 ⁇ m.
  • the cells in these clusters were referred to as CS (cardiac precursors from spoc) cells.
  • CS cells were gently collected after seven days of growth in complete growth medium. The cells were then plated in the same medium in the absence of EGF and bFGF (differentiation medium) and were maintained at 37° C. To assess the progression of differentiation of the cells, the cultures were observed at various time points using an inverted light microscope. Beating frequency measurements of the cardiomyocytes were obtained by video microscopy.
  • the specimens were rinsed 3 times (5 minutes each) with PBS and blocked again with goat serum for 30 minutes.
  • the specimens were then incubated at room temperature with a secondary antibody, conjugated with either Fluorescein Isothiocyanate (FITC), Texas Red, or Tetramethylrhodamine Isothiocyanate (TRITC), for 1 hour. They were again rinsed 3 times (5 minutes each) with PBS and then visualized with a laser confocal microscope (Leica) to detect fluorescent signals.
  • FITC Fluorescein Isothiocyanate
  • Texas Red Texas Red
  • TRITC Tetramethylrhodamine Isothiocyanate
  • the earliest time of GATA-4 expression is after 3 days in culture in growth factor containing medium. Within 3 days after replating the cells in differentiation medium, some cells begin to express sarcomeric myosin. Cytospins of day 7 CS cells stained with monoclonal antibodies demonstrate the expression of cardiac-specific transcription factor GATA-4, sarcomeric myosin, and cardiac-specific troponin-T. Day 14 cells stained for GATA-4 and sarcomeric myosin. Overlays of images of cells stained with GATA-4 and sarcomeric myosin demonstrated that they were co-localized in the cell. At this early stage in development some cells may either be positive for GATA-4 or sarcomeric myosin. By day 28, the majority of cells express both proteins. By day 21 the cells are positive for cardiac L-type calcium channel, cardiac-specific transcription factor Nkx2.5, and connexin 43.
  • FIG. 1 transmission electron micrographs show the progression of CS cells.
  • FIG. 1A round cells with disordered myosin filaments (FIG. 1A) and large central nuclei surrounded by copious mitochondria (FIG. 1D, box and detail) exist.
  • FIG. 1E elongated cells
  • Myosin filaments of characteristic 1.6 ⁇ m-length FIG. 1B, top box
  • a day 14 cell FIGGS. 1C and F
  • FIG. 1G. 1G shows a stretching out of the dense bodies (FIG. 1C) into an organizing sarcomere.
  • a well-defined sarcomere FIG. 1G is present, with identifiable A- and I-bands and Z-lines.
  • Cardiomyocytes were incubated for 30 minutes at 37° C. with fluo-3 or fluo-4 dye at a concentration of approximately 5-10 ⁇ m in DMEM/F-12 (dyes dissolved in DMSO 1:1 with pluronic solution). The cells were then washed with fresh DMEM/F-12. The images were collected with a Zeiss LSM-510 laser scanning confocal system and a C-Apochromat 63 ⁇ objective (1.2 N.A.). Fluo-3 and fluo-4 were excited at 488 nm with an argon laser and the emission light was collected using an LP 505 filter. The pinhole was adjusted to produce a 5 ⁇ m slice to minimize the influence of axial movements with contraction on viewing the calcium transients. All transmitted light images were collected simultaneously using a transmitted light detector in conjunction with the 488 nm excitation light. Data depth for the images was 8-bit.
  • FIG. 2A shows a graphical representation of the calcium transient in a beating CS cell-derived cardiomyocyte. Peak intensity and baseline are shown in FIG. 2B and FIG. 2C, respectively. In some CS cells, calcium transients can be seen before observable contractions are noted, suggesting the development of cardiomyocyte excitation elements in advance of maturing contractile elements.
  • Spoc cells are c-kit ⁇ , distinguishing them from the c-kit+ bone marrow cells that have been used directly or indirectly in experiments to reconstitute infarcted heart.
  • spoc cells could be derived from circulating bone marrow cells that become c-kit ⁇ after migration to skeletal muscle.
  • whole bone marrow was fractionated into c-kit+ and c-kit ⁇ populations. Both separate and combined populations were cultured under the same conditions as spoc cells. None of the 3 marrow cell populations developed into spontaneously beating cells.
  • MSC mesenchymal stem cells
  • Skeletal muscle tissue is surgically obtained from the deltoid muscle of an adult human, is cut into small pieces and is digested with collagenase for two hours at 37° C.
  • the digested tissue is cleared of cell debris and other undigested tissue fragments by passage through a 100 ⁇ m filter and then through a 40 ⁇ m filter.
  • the cell suspension is centrifuged at low speed to clear as much as of the small muscle fiber fragments as possible.
  • the cells at this stage consist mostly of clusters of small round cells approximately 4 ⁇ m in diameter which are the human spoc cells. These cells do not express the satellite cell surface marker c-met.
  • the spoc cells are plated at a density of approximately 10 5 cells per cm 2 in regular tissue culture dishes in complete growth medium (1:1 DMEM/F12 supplemented with 5% fetal bovine serum (FBS), 10 ng/ml human EGF, 10 ng/ml human bFGF (PeproTech, Inc.), 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 6 ng/ml selenium, 2 ⁇ g/ml ethanolamine (ITS-X, Invitrogen Corporation), 25 ⁇ g/ml gentamicin and 2.5 ⁇ g/ml fungizone (Life Technologies)).
  • FBS fetal bovine serum
  • 10 ng/ml human EGF 10 ng/ml human bFGF
  • 5 ⁇ g/ml insulin 5 ⁇ g/ml transferrin
  • 6 ng/ml selenium 2 ⁇ g/ml ethanolamine (ITS-X, Invitrogen Corporation)
  • ITS-X
  • the culture After a few days, the culture consists of a floating population of round cells and some adherent fibroblasts.
  • the round cells enlarge as they undergo a few rounds of cell division during which time they become clusters of floating round cells with an increased diameter of 10-14 ⁇ m.
  • the cells in these clusters were referred to as CS (cardiac precursors from spoc) cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
US10/003,400 2001-10-22 2001-10-22 Stem cells that transform to beating cardiomyocytes Abandoned US20030082153A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/003,400 US20030082153A1 (en) 2001-10-22 2001-10-22 Stem cells that transform to beating cardiomyocytes
JP2003538339A JP4377690B2 (ja) 2001-10-22 2002-10-22 拍動する心筋細胞へ形質転換する幹細胞
AT02773854T ATE348878T1 (de) 2001-10-22 2002-10-22 Sich in schlagende kardiomyozyten verwandelnde stammzellen
AU2002337949A AU2002337949B1 (en) 2001-10-22 2002-10-22 Stem cells that transform to beating cardiomyocytes
PCT/US2002/033860 WO2003035838A2 (fr) 2001-10-22 2002-10-22 Cellules souches se transformant en cardiomyocytes a battements spontanes
CA002464088A CA2464088A1 (fr) 2001-10-22 2002-10-22 Cellules souches se transformant en cardiomyocytes a battements spontanes
EP02773854A EP1444329B1 (fr) 2001-10-22 2002-10-22 Cellules souches se transformant en cardiomyocytes a battements spontanes
DE60216959T DE60216959D1 (de) 2001-10-22 2002-10-22 Sich in schlagende kardiomyozyten verwandelnde stammzellen
US10/863,004 US7220582B2 (en) 2001-10-22 2004-06-07 Stem cells that transform to beating cardiomyocytes
US11/747,060 US20070212423A1 (en) 2001-10-22 2007-05-10 Stem cells that transform to beating cardiomyocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/003,400 US20030082153A1 (en) 2001-10-22 2001-10-22 Stem cells that transform to beating cardiomyocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/863,004 Continuation US7220582B2 (en) 2001-10-22 2004-06-07 Stem cells that transform to beating cardiomyocytes

Publications (1)

Publication Number Publication Date
US20030082153A1 true US20030082153A1 (en) 2003-05-01

Family

ID=21705682

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/003,400 Abandoned US20030082153A1 (en) 2001-10-22 2001-10-22 Stem cells that transform to beating cardiomyocytes
US10/863,004 Expired - Fee Related US7220582B2 (en) 2001-10-22 2004-06-07 Stem cells that transform to beating cardiomyocytes
US11/747,060 Abandoned US20070212423A1 (en) 2001-10-22 2007-05-10 Stem cells that transform to beating cardiomyocytes

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/863,004 Expired - Fee Related US7220582B2 (en) 2001-10-22 2004-06-07 Stem cells that transform to beating cardiomyocytes
US11/747,060 Abandoned US20070212423A1 (en) 2001-10-22 2007-05-10 Stem cells that transform to beating cardiomyocytes

Country Status (8)

Country Link
US (3) US20030082153A1 (fr)
EP (1) EP1444329B1 (fr)
JP (1) JP4377690B2 (fr)
AT (1) ATE348878T1 (fr)
AU (1) AU2002337949B1 (fr)
CA (1) CA2464088A1 (fr)
DE (1) DE60216959D1 (fr)
WO (1) WO2003035838A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126879A1 (en) * 2002-08-29 2004-07-01 Baylor College Of Medicine Heart derived cells for cardiac repair
US20050221480A1 (en) * 2002-03-06 2005-10-06 Trans-Science, Inc. Self-renewing pluripotent hepatic stem cells
WO2006020322A3 (fr) * 2004-07-19 2006-07-27 Univ Columbia Systeme d'essai permettant de suivre de cellules transformees par genie genetique pour modifier les fonctions d'un syncytium
US7166280B2 (en) 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20080213231A1 (en) * 2005-07-15 2008-09-04 Kyoto University Pluripotent Stem Cell Cloned From Single Cell Derived From Skeletal Muscle Tissue
US20080241111A1 (en) * 2005-03-04 2008-10-02 Kyoto University Pluripotent Stem Cell Derived from Cardiac Tissue
EP1696995A4 (fr) * 2003-12-24 2009-03-04 Medtronic Inc Procedes d'utilisation des genes hcn pour le traitement d'arythmies cardiaques
US20100278787A1 (en) * 2007-07-18 2010-11-04 Cellartis Ab Cardiomyocyte-like cell clusters derived from hbs cells
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US9867854B2 (en) 2005-03-04 2018-01-16 Kyoto University Therapeutic method using cardiac tissue-derived pluripotent stem cells

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39890E1 (en) 1991-03-27 2007-10-23 Matsushita Electric Industrial Co., Ltd. Communication system
USRE40241E1 (en) 1991-03-27 2008-04-15 Matsushita Electric Industrial Co., Ltd. Communication system
USRE42643E1 (en) 1991-03-27 2011-08-23 Panasonic Corporation Communication system
US6724976B2 (en) * 1992-03-26 2004-04-20 Matsushita Electric Industrial Co., Ltd. Communication system
US5819000A (en) * 1992-03-26 1998-10-06 Matsushita Electric Industrial Co., Ltd. Magnetic recording and playback apparatus
US5802241A (en) 1992-03-26 1998-09-01 Matsushita Electric Industrial Co., Ltd. Communication system
US7894541B2 (en) * 1992-03-26 2011-02-22 Panasonic Corporation Communication system
US6728467B2 (en) * 1992-03-26 2004-04-27 Matsushita Electric Industrial Co., Ltd. Communication system
USRE38513E1 (en) 1992-03-26 2004-05-11 Matsushita Electric Industrial Co., Ltd. Communication system
US7158577B1 (en) 1992-03-26 2007-01-02 Matsushita Electric Industrial Co., Ltd. Communication system
FR2819265B1 (fr) * 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
WO2005047482A2 (fr) 2003-11-12 2005-05-26 Xiao Xu Systemes de detection de cellules electroniques en temps reel pour des epreuves a base de cellules
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US10539523B2 (en) 2002-12-20 2020-01-21 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
US10215748B2 (en) 2002-12-20 2019-02-26 Acea Biosciences, Inc. Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
US10551371B2 (en) 2003-11-10 2020-02-04 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function
ITRM20030376A1 (it) * 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
CA2555376A1 (fr) * 2004-02-06 2005-08-25 Theradigm, Inc. Compositions et methodes concernant la culture de cellules souches neurales avec des cellules stromales de moelle osseuse
WO2005095652A2 (fr) 2004-03-31 2005-10-13 Georgetown University Pnmt en tant que nouveau marqueur de cellules progenitrices
AU2005246216B2 (en) * 2004-04-23 2011-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of a monoclonal antibody that specifically binds stem cells
DK1745144T3 (da) 2004-05-11 2011-02-07 Axiogenesis Ag Analysefremgangsmåde til opsporing af lægemidler på grundlag af in vitro-differentierede celler
WO2006011354A1 (fr) * 2004-07-27 2006-02-02 Kowa Company, Ltd. Promoteur de fusion de cellules et utilisation de celui-ci
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
CN103356704B (zh) * 2005-03-31 2015-09-30 斯丹姆涅恩有限公司 制备用以治疗由糖尿病性神经病引发的溃疡的药物的方法
FR2896511B1 (fr) * 2006-01-26 2012-10-26 Centre Nat Rech Scient Procede de culture de cellules issues du tissu adipeux et leurs applications.
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
US20080089874A1 (en) * 2006-09-28 2008-04-17 The Regents Of The University Of California Directed differentiation and maturation of stem cell-derived cardiomyocytes
WO2008043099A2 (fr) 2006-10-06 2008-04-10 Medtronic, Inc. systÈme de stimulation cardiaque hybride
KR101240487B1 (ko) * 2006-11-09 2013-03-08 더 존스 홉킨스 유니버시티 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화
US9045731B2 (en) 2007-09-12 2015-06-02 The Regents Of The University Of California Compositions and methods for improving the functional efficacy of stem cell-derived cardiomyocytes
US20090186414A1 (en) * 2008-01-18 2009-07-23 Deepak Srivastava Methods of Generating Cardiomyocytes and Cardiac Progenitors and Compositions
WO2009120762A2 (fr) 2008-03-27 2009-10-01 Mount Sinai School Of Medicine Of New York University Cellules progénitrices cardio-vasculaires humaines
WO2009137440A1 (fr) 2008-05-05 2009-11-12 Acea Biosciences, Inc. Surveillance sans marqueur d’un couplage excitation-contraction et cellules pouvant être excitées utilisant des systèmes fondés sur l'impédance avec une résolution dans le temps de l'ordre de la milliseconde
WO2011005930A1 (fr) * 2009-07-09 2011-01-13 Centocor Ortho Biotech Inc. Cellules dérivées de tissus cardiaques
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2011146531A1 (fr) * 2010-05-18 2011-11-24 Acea Biosciences, Inc Analyse de données de signaux de battements de cardiomyocytes à base d'impédance tels que détectés sur des instruments cardiologiques d'analyse de cellules en temps réel (rtca)
WO2012098260A1 (fr) 2011-01-21 2012-07-26 Axiogenesis Ag Système non viral pour générer des cellules souches pluripotentes induites (ips)
CA2846285C (fr) * 2011-10-17 2019-09-24 F. Hoffmann-La Roche Ag Diagnostic de patients a risque et de cause d'accident vasculaire cerebral fonde sur les peptides bnp et la troponine
EP2861238A4 (fr) * 2012-06-05 2016-03-16 Capricor Inc Procédés optimisés pour générer des cellules souches cardiaques à partir de tissu cardiaque et leur utilisation dans une thérapie cardiaque
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
WO2014104364A1 (fr) * 2012-12-28 2014-07-03 国立大学法人京都大学 Méthode de production de cellules souches pluripotentes induites, cardiomyocytes ou cellules précurseurs correspondantes
JP2016505276A (ja) 2013-01-23 2016-02-25 リー、ロナルドLI, Ronald 幹細胞由来心筋細胞の操作された物理的アライメント
US9493742B2 (en) 2013-03-15 2016-11-15 Emory University Purification of cell mixtures using molecular beacons targeting cell specific RNA
US10087436B2 (en) 2014-02-06 2018-10-02 The Regents Of The University Of California Electrophysiologically mature cardiomyocytes and methods for making same
EP3200808B1 (fr) 2014-10-03 2024-07-31 Cedars-Sinai Medical Center Cellules dérivées de la cardiosphère et exosomes sécrétés par ces cellules dans le traitement d'une dystrophie musculaire
US12066428B2 (en) 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (fr) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center Cellules dérivées de cardiosphères et leurs vésicules extracellulaires pour retarder ou inverser le vieillissement et des troubles liés à l'âge
CN118460528A (zh) 2017-03-03 2024-08-09 安捷伦科技有限公司 用于iPSC和ESC衍生的心肌细胞的功能成熟的方法和系统
EP3612191A4 (fr) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center Méthodes et compositions pour traiter une dystrophie musculaire squelettique
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (fr) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Procédés d'utilisation thérapeutique d'exosomes et d'arn y
USD941488S1 (en) 2020-02-07 2022-01-18 Agilent Technologies, Inc. Instrument for analyzing biological cells
US20210301245A1 (en) 2020-03-29 2021-09-30 Agilent Technologies, Inc. Systems and methods for electronically and optically monitoring biological samples

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387369B1 (en) 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO2000006701A1 (fr) 1998-07-31 2000-02-10 Genzyme Corporation Amelioration du fonctionnement cardiaque par transplantation de cellules souches mesenchymateuses
WO2001000031A1 (fr) 1999-06-25 2001-01-04 Baylor College Of Medicine Cellules souches derivees du muscle squelettique
PT1226233E (pt) 1999-08-05 2011-10-04 Abt Holding Co Células estaminais adultas multipotentes e métodos para isolamento
AU5159901A (en) * 2000-04-14 2001-10-30 Univ Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US7166280B2 (en) 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20070196343A1 (en) * 2000-04-06 2007-08-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20050221480A1 (en) * 2002-03-06 2005-10-06 Trans-Science, Inc. Self-renewing pluripotent hepatic stem cells
US20040126879A1 (en) * 2002-08-29 2004-07-01 Baylor College Of Medicine Heart derived cells for cardiac repair
US8859273B2 (en) 2003-12-24 2014-10-14 Medtronic, Inc. Methods of using HCN genes to treat cardiac arrhythmias
EP1696995A4 (fr) * 2003-12-24 2009-03-04 Medtronic Inc Procedes d'utilisation des genes hcn pour le traitement d'arythmies cardiaques
WO2006020322A3 (fr) * 2004-07-19 2006-07-27 Univ Columbia Systeme d'essai permettant de suivre de cellules transformees par genie genetique pour modifier les fonctions d'un syncytium
US20100068699A1 (en) * 2004-07-19 2010-03-18 Robinson Richard B Assay System For Monitoring The Effects Of Genetically Engineered Cells To Alter Function Of A Synctium
US8192929B2 (en) 2004-07-19 2012-06-05 The Trustees Of Columbia University In The City Of New York Assay system for monitoring the effects of genetically engineered cells to alter function of a synctium
US20080241111A1 (en) * 2005-03-04 2008-10-02 Kyoto University Pluripotent Stem Cell Derived from Cardiac Tissue
US9867854B2 (en) 2005-03-04 2018-01-16 Kyoto University Therapeutic method using cardiac tissue-derived pluripotent stem cells
US20080213231A1 (en) * 2005-07-15 2008-09-04 Kyoto University Pluripotent Stem Cell Cloned From Single Cell Derived From Skeletal Muscle Tissue
US20100278787A1 (en) * 2007-07-18 2010-11-04 Cellartis Ab Cardiomyocyte-like cell clusters derived from hbs cells

Also Published As

Publication number Publication date
CA2464088A1 (fr) 2003-05-01
DE60216959D1 (de) 2007-02-01
JP4377690B2 (ja) 2009-12-02
ATE348878T1 (de) 2007-01-15
AU2002337949B1 (en) 2003-05-06
WO2003035838A3 (fr) 2003-07-17
EP1444329A4 (fr) 2004-11-24
JP2005506845A (ja) 2005-03-10
EP1444329A2 (fr) 2004-08-11
US7220582B2 (en) 2007-05-22
US20050058633A1 (en) 2005-03-17
WO2003035838A2 (fr) 2003-05-01
US20070212423A1 (en) 2007-09-13
EP1444329B1 (fr) 2006-12-20

Similar Documents

Publication Publication Date Title
US7220582B2 (en) Stem cells that transform to beating cardiomyocytes
Lee et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing
JP4562816B2 (ja) 心筋再生のための間葉幹細胞の使用法および組成物
US8852575B2 (en) Cardiac muscle repair or regeneration using bone marrow-derived stem cells
US10709742B2 (en) Method to amplify cardiac stem cells in vitro and in vivo
US20100291610A1 (en) Regulating Stem Cells
JP2007143554A (ja) 細胞移植方法及び試薬
KR100694442B1 (ko) 인캡슐화된 세포 인디케이터 시스템
EP2205251B1 (fr) Procédé pour amplifier des cellules cardiaques souches in vitro et in vivo
WO2006021459A1 (fr) Compositions et methodes destinees a la modulation de la differenciation cellulaire
WO2015097259A1 (fr) Populations de cellules dérivées de muscles ayant des capacités de différenciation cardiogénique
JP4083024B6 (ja) 細胞移植方法及び試薬
WO2006021460A1 (fr) Moyens et procedes pour generer des cardiomyocytes et un tissu correspondant ainsi que leur utilisation

Legal Events

Date Code Title Description
AS Assignment

Owner name: HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EPSTEIN, NEAL D.;GOPAL, THIRU V.;WINITSKY, STEVEN;AND OTHERS;REEL/FRAME:012909/0059

Effective date: 20020417

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION